Further therapeutic exploration indicated that treating melanoma cells via the activation of ZBP1-induced PANoptosis offers PANoptosis as a critical innate immune biomarker that can be targeted to improve patient outcomes in cancers 114. This evidence concerns the gene ZBP1 and cancer.